Skip to main content

Dipeptidyl peptidase-4 (DPP-4) inhibitors

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

Further support for early combination therapy in type 2 diabetes

Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.

Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews top story

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.

medwireNews editor's pick

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Journal article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more].
Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

Get more on:  Diabetic complications | Medication | Type 2 diabetes

Journal article

Glycemic impact of non-nutritive sweeteners: A systematic review and meta-analysis of randomized controlled trials

A systematic review and meta-analysis of randomized controlled trials was conducted to quantitatively synthesize existing scientific evidence on the glycemic impact of non-nutritive sweeteners [read more].
Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

Get more on: Type 2 diabetes | Glycemic control | Diet and nutritional management

medwireNews editor's pick

Modern antidiabetic medications ranked for survival benefits

A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.

Journal article

Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: Interim report from post-marketing surveillance

In this interim analysis, we evaluated the long-term safety and efficacy of teneligliptin in a subgroup of type 2 diabetes patients with renal impairment using case report forms [read more].
Haneda M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0416-2

Get more on: Type 2 diabetesDPP-4 inhibitors | Glycemic control

medwireNews editor's pick

Support for alogliptin as add-on therapy for type 2 diabetes

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

medwireNews

31-08-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

03-02-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

09-12-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

Themed collections

New Content Item

22-05-2017 | Heart failure | Themed collection | Collection

Heart failure and diabetes mellitus

This collection provides an overview of the epidemiology, underlying pathophysiological mechanisms, screening, assessment and management of heart failure in patients with diabetes mellitus.

Journal articles and book chapters

16-08-2018 | DPP-4 inhibitors | Review | Article

Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

Guidelines

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Downloadable slides

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

In practice

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.